XML 30 R21.htm IDEA: XBRL DOCUMENT v3.22.4
Share-Based Payments (Tables)
 9 Months Ended
Jan. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Summary of allocation of share based compensation expense
Stock-based compensation expense was recognized as follows (table in thousands):
 
Three Months Ended
January 31,		Nine Months Ended
January 31,
 2023202220232022
General and administrative$235 $223 $380 $442 
Sales and marketing50 53 148 149 
Research and development6 3 13 17 
Cost of oncology services40 31 115 116 
Total stock-based compensation expense$331 $310 $656 $724 
Summary of valuation assumptions for stock options Black-Scholes assumptions used to calculate the fair value of options granted during the three and nine months ended January 31, 2023 and 2022 were as follows:
 
Three Months Ended
January 31,		Nine Months Ended
January 31,
 2023202220232022
Expected term in years
6
6
6
6
Risk-free interest rates
3.70%
1.11% - 1.20%
2.87% - 3.70%
0.82% - 1.20%
Volatility
61.88%
64.37% - 64.62%
61.88% - 62.58%
64.37%-66.21%
Dividend yield—%—%—%—%
Summary of stock option activity
The Company’s stock options activity for the nine months ended January 31, 2023 was as follows:
 
Directors
and
Employees		Non-
Employees		TotalWeighted
Average
Exercise
Price		Weighted
Average
Remaining
Contractual
Life (Years)		Aggregate
Intrinsic
Value
Outstanding, April 30, 20221,617,324 40,915 1,658,239 $4.51 4.9$6,131,000 
Granted184,720 — 184,720 7.25 9.6
Exercised(36,209)— (36,209)3.21 
Forfeited(9,125)— (9,125)7.94   
Canceled(13,874)— (13,874)3.93 
Expired— (4,584)(4,584)5.40   
Outstanding, January 31, 20231,742,836 36,331 1,779,167 4.81 4.8$1,896,000 
Vested and expected to vest as of January 31, 20231,742,836 36,331 1,779,167 4.81 4.8$1,896,000 
Exercisable as of January 31, 20231,389,002 1,875 1,390,877 4.24 3.9$1,896,000